MX2019010230A - Composiciones y metodos del inhibidor de granzima b para la prevencion y/o el tratamiento de la formacion de ampollas en la piel y/o descamacion cutanea. - Google Patents
Composiciones y metodos del inhibidor de granzima b para la prevencion y/o el tratamiento de la formacion de ampollas en la piel y/o descamacion cutanea.Info
- Publication number
- MX2019010230A MX2019010230A MX2019010230A MX2019010230A MX2019010230A MX 2019010230 A MX2019010230 A MX 2019010230A MX 2019010230 A MX2019010230 A MX 2019010230A MX 2019010230 A MX2019010230 A MX 2019010230A MX 2019010230 A MX2019010230 A MX 2019010230A
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- methods
- granzyme
- peeling
- prevention
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 229940121832 Granzyme B inhibitor Drugs 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465055P | 2017-02-28 | 2017-02-28 | |
| US201762611188P | 2017-12-28 | 2017-12-28 | |
| PCT/CA2018/050230 WO2018157244A1 (en) | 2017-02-28 | 2018-02-28 | Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010230A true MX2019010230A (es) | 2019-11-21 |
Family
ID=63369653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010230A MX2019010230A (es) | 2017-02-28 | 2018-02-28 | Composiciones y metodos del inhibidor de granzima b para la prevencion y/o el tratamiento de la formacion de ampollas en la piel y/o descamacion cutanea. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200016125A1 (enExample) |
| EP (1) | EP3589304A4 (enExample) |
| JP (2) | JP2020510655A (enExample) |
| KR (1) | KR20190140907A (enExample) |
| AU (1) | AU2018229079A1 (enExample) |
| IL (1) | IL268860A (enExample) |
| MX (1) | MX2019010230A (enExample) |
| WO (1) | WO2018157244A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220332805A1 (en) * | 2019-09-11 | 2022-10-20 | University Of Cincinnati | Treatment of Skin Blistering Diseases Using Antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016015160A1 (en) * | 2014-08-01 | 2016-02-04 | Vida Therapeutics, Inc. | Cyclic urea compounds as granzyme b inhibitors |
| WO2017132771A1 (en) * | 2016-02-03 | 2017-08-10 | Vida Therapeutics, Inc. | Granzyme b inhibitor formulations and methods for the treatment of burns |
-
2018
- 2018-02-28 US US16/489,117 patent/US20200016125A1/en not_active Abandoned
- 2018-02-28 AU AU2018229079A patent/AU2018229079A1/en not_active Abandoned
- 2018-02-28 WO PCT/CA2018/050230 patent/WO2018157244A1/en not_active Ceased
- 2018-02-28 KR KR1020197028544A patent/KR20190140907A/ko not_active Withdrawn
- 2018-02-28 JP JP2019546391A patent/JP2020510655A/ja active Pending
- 2018-02-28 EP EP18760824.5A patent/EP3589304A4/en not_active Withdrawn
- 2018-02-28 MX MX2019010230A patent/MX2019010230A/es unknown
-
2019
- 2019-08-22 IL IL26886019A patent/IL268860A/en unknown
-
2022
- 2022-08-25 US US17/822,211 patent/US20230233526A1/en not_active Abandoned
-
2023
- 2023-02-21 JP JP2023025114A patent/JP2023062141A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3589304A1 (en) | 2020-01-08 |
| JP2020510655A (ja) | 2020-04-09 |
| AU2018229079A1 (en) | 2019-10-10 |
| JP2023062141A (ja) | 2023-05-02 |
| EP3589304A4 (en) | 2020-11-25 |
| KR20190140907A (ko) | 2019-12-20 |
| WO2018157244A1 (en) | 2018-09-07 |
| IL268860A (en) | 2019-10-31 |
| US20200016125A1 (en) | 2020-01-16 |
| US20230233526A1 (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| WO2014188276A3 (en) | Antioxidant compositions and methods of using the same | |
| MX2017015896A (es) | Agente anticancerigeno. | |
| PH12014502029A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2021013318A (es) | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| NZ582556A (en) | Pharmaceutical composition for treating wounds and related methods | |
| MX2020001727A (es) | Terapia de combinacion. | |
| GB2541854A (en) | Patterned surfaces | |
| EP4385576A3 (en) | Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension | |
| GEP20227384B (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment |